Characterization of Sequelae Reported by SUS Users Recovered from COVID-19 in a Neighborhood of Serra Catarinense Municipality

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

Dutasteride often stops hair loss quickly, with some users noticing reduced shedding and thicker hair within a few months. Some users combine it with minoxidil for better results, though side effects like lower libido and initial shedding are common.

Low doses of dutasteride are as effective as higher doses for hair regrowth, with fewer side effects. Users find success taking it 2-3 times a week instead of daily.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.